Health Care • Medical/Dental Instruments
$13.84 ▼ -0.23
(-1.63%)
MKT CAP: $280.2M • VOL: 256.5K
52W L $7 52W H $15
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$12
MEDIAN
$16
MEAN
$16
HIGH
$19
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE INFU TAPE
INFU // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $16.75 | $15.92 | 2025-02-14 | $12.59 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $17.44 | $16.33 | 2025-02-06 | $13.01 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $15.78 | $15.22 | 2025-01-29 | $13.29 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $14.12 | — | 2025-01-17 | $13.56 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $12.18 | $13.15 | 2025-01-09 | $12.32 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $16.47 | $14.39 | 2024-12-18 | $12.04 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $13.42 | $13.98 | 2024-12-04 | $12.87 | -4.3% | 48% | C |